Peptide Antibiotics Market Expected To Reach $9.04 Billion By 2030 As Growth Accelerates At 9.3% CAGR
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Peptide Antibiotics Market Size And Revenue Forecast Through 2030
Recent years have seen significant expansion in the peptide antibiotics market, with its size reaching $5.77 billion in 2025 and projected to climb to $6.32 billion by 2026, reflecting a compound annual growth rate of 9.6%. Several factors underpinned this historical growth: the emergence of antibiotic-resistant bacterial strains, rising rates of infections acquired in hospitals, improved peptide synthesis technologies, expanding clinical studies focused on infectious diseases, and increased government investment in peptide antibiotics research and development.
Strong expansion is projected for the peptide antibiotics market over the coming years, with its value expected to reach $9.04 billion by 2030, reflecting a compound annual growth rate (CAGR) of 9.3%. This anticipated growth during the forecast period is driven by factors such as the increasing frequency of multi-drug resistant infections, improvements in global healthcare infrastructure, progress in peptide delivery technologies, heightened partnerships with CDMOs, and a growing recognition and implementation of precision medicine strategies. Key developments shaping this period include a rising need for solutions targeting multi-drug resistant (MDR) infections, the broader application of peptide antibiotics in treating hospital-acquired infections, the expansion of contract manufacturing and CDMO collaborations, a move toward more personalized and targeted antibiotic therapies, and a stronger emphasis on creating peptide antibiotics with lower toxicity and fewer side effects.
Download A Free Sample Report For Comprehensive Market Insights:
Peptide Antibiotics Market Growth Drivers: What Factors Are Accelerating Expansion?
Peptide antibiotics market growth is anticipated to be driven by the rising prevalence of infectious diseases. These diseases, resulting from harmful microorganisms like bacteria, fungi, and parasites, have seen an uptick due to factors such as rapid urbanization, climate change, and heightened disease emergence risks, thereby boosting demand for peptide antibiotics. Such antibiotics work by physically disrupting cell membranes to achieve antibacterial effects. As an example, the World Health Organization, an intergovernmental entity based in Switzerland, reported in May 2024 that dengue case numbers in the Americas had exceeded seven million by April 2024, a stark rise from the 4.6 million cases recorded throughout 2023. Consequently, the growing occurrence of infectious conditions is fueling expansion in the peptide antibiotics market.
The peptide antibiotics market is being stimulated by a growing occurrence of chronic diseases. Chronic illnesses, defined by their duration of a year or more, necessitate ongoing medical care and can hinder everyday activities. Their prevalence is increasing due to trends like higher tobacco consumption, poor dietary habits, physical inactivity, and excessive alcohol intake. Peptide antibiotics are utilized in treating these conditions by delivering medication directly to the targeted area. For instance, in February 2024, the World Health Organization, a Switzerland-headquartered intergovernmental agency, projected that by 2050, over 35 million new cancer cases would arise—a 77% jump from the estimated 20 million cases in 2022. Thus, the escalating prevalence of chronic ailments is propelling the peptide antibiotics market forward.
Peptide Antibiotics Market Segment Outlook: Which Categories Are Expanding The Fastest?
The peptide antibiotics market covered in this report is segmented –
1) By Type: Ribosomal Synthesized Peptide Antibiotics, Non-Ribosomal Synthesized Peptide Antibiotics
2) By Drugs: Daptomycin, Dalbavancin, Telavancin, Other Drugs
3) By Disease Outlook: Skin Infection, HABP Or VABP, Blood Stream Infection, Other Diseases
4) By Distribution Channel: Hospitals, Homecare, Specialty Clinics, Other Distribution Channels
Subsegments:
1) By Ribosomal Synthesized Peptide Antibiotics: Aminoglycosides, Macrolides, Tetracyclines, Lincosamides
2) By Non-Ribosomal Synthesized Peptide Antibiotics: Bacitracins, Vancomycin, Polymyxins, Cyclic Lipopeptides
Peptide Antibiotics Market Trends: What Is Shaping Future Industry Growth?
Major players in the peptide antibiotics sector are introducing generic alternatives to offer patients a more budget-friendly treatment option. These generic drugs represent cost-effective, patent-free substitutes for branded peptide-based antibiotics, which are employed in managing a range of bacterial infections. As an example, in July 2023, Camber Pharmaceuticals, a pharmaceutical firm based in the United States, broadened its product range by rolling out a generic form of Daptomycin for Injection. This product falls under the category of peptide antibiotics; specifically, it is a cyclic lipopeptide antibiotic produced via a non-ribosomal mechanism. The generic version is supplied in 350 mg and 500 mg doses, and it is indicated for managing complicated skin and skin structure infections (cSSSI) in adult individuals as well as pediatric patients from 1 to 17 years old.
Peptide Antibiotics Market Key Companies And Competitive Benchmarking
Major companies operating in the peptide antibiotics market are Eli Lilly and Company, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sandoz International GmbH, Xellia APS, Johnson & Johnson Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Lupin Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Wockhardt Ltd., Zydus Lifesciences Limited, Alkem Laboratories Limited, Allecra Therapeutics GmbH, Basilea Pharmaceutica Ltd.
Access The Complete Peptide Antibiotics Market Report:
Peptide Antibiotics Market Geographic Analysis: Where Is Demand Growing The Fastest?
North America was the largest region in the peptide antibiotics market in 2025. The regions covered in the peptide antibiotics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
